García-Otín A L, Civeira F, Peinado-Onsurbe J, Gonzalvo C, Llobera M, Pocoví M
Departments of Biochemistry, Molecular Biology and Medicine, University of Zaragoza, Hospital Miguel Servet, Av. Isabel La Católica 1-3, 50009, Zaragoza, Spain.
Eur J Endocrinol. 1999 Nov;141(5):502-5. doi: 10.1530/eje.0.1410502.
Type I hyperlipoproteinemia (type I HLP) is a rare disorder of lipid metabolism characterized by fasting chylomicronemia and reduced postheparin plasma lipoprotein lipase (LPL) activity. Most cases of type I HLP are due to genetic defects in the LPL gene or in its activator, the apolipoprotein CII gene. Several cases of acquired type I HLP have also been described in the course of autoimmune diseases due to the presence of circulating inhibitors of LPL. Here we report a case of type I HLP due to a transient defect of LPL activity during puberty associated with chronic idiopathic urticaria (CIU). The absence of any circulating LPL inhibitor in plasma during the disease was demonstrated. The LPL genotype showed that the patient was heterozygous for the D9N variant. This mutation, previously described, can explain only minor defects in the LPL activity. The presence of HLP just after the onset of CIU, and the elevation of the LPL activity with remission of the HLP when the patient recovered from CIU, indicate that type I HLP was caused by CIU. In summary, we report a new etiology for type I HLP - a transient decrease in LPL activity associated with CIU and with absence of circulating inhibitors. This is the first description of this association, which suggests a new mechanism for type I HLP.
I型高脂蛋白血症(I型HLP)是一种罕见的脂质代谢紊乱疾病,其特征为空腹乳糜微粒血症和肝素后血浆脂蛋白脂肪酶(LPL)活性降低。大多数I型HLP病例是由于LPL基因或其激活剂载脂蛋白CII基因的遗传缺陷所致。在自身免疫性疾病过程中,由于存在LPL循环抑制剂,也有几例获得性I型HLP的报道。在此,我们报告一例I型HLP病例,其病因是青春期LPL活性的短暂缺陷,并伴有慢性特发性荨麻疹(CIU)。在疾病期间,血浆中未检测到任何循环LPL抑制剂。LPL基因分型显示,患者为D9N变异体的杂合子。先前已描述过这种突变,它只能解释LPL活性的轻微缺陷。CIU发病后立即出现HLP,而患者从CIU恢复时HLP缓解且LPL活性升高,这表明I型HLP是由CIU引起的。总之,我们报告了I型HLP的一种新病因——与CIU相关且无循环抑制剂的LPL活性短暂降低。这是这种关联的首次描述,提示了I型HLP的一种新机制。